Cargando…

Off‐label and unlicensed medicines to hospitalised children in Norway

OBJECTIVES: The aim of this study was to investigate the use of off‐label (OL) and unlicensed (UL) medicines to hospitalised children in Norway, to add to the current knowledge on use of medicines in this vulnerable patient group. METHODS: The study was performed as a cross‐sectional prospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Teigen, Arna, Wang, Siri, Truong, Bich Thuy, Bjerknes, Kathrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396330/
https://www.ncbi.nlm.nih.gov/pubmed/27334565
http://dx.doi.org/10.1111/jphp.12581
_version_ 1783230047045287936
author Teigen, Arna
Wang, Siri
Truong, Bich Thuy
Bjerknes, Kathrin
author_facet Teigen, Arna
Wang, Siri
Truong, Bich Thuy
Bjerknes, Kathrin
author_sort Teigen, Arna
collection PubMed
description OBJECTIVES: The aim of this study was to investigate the use of off‐label (OL) and unlicensed (UL) medicines to hospitalised children in Norway, to add to the current knowledge on use of medicines in this vulnerable patient group. METHODS: The study was performed as a cross‐sectional prospective study. Medication was classified as on‐ or off‐label based on the comparison with the SmPC regarding age, indication, dosage, route of administration and handling of the product. UL products were classified as imported or pharmacy produced. KEY FINDINGS: More than 90% of children receiving medicines in our study were given OL or UL medicines. More patients received OL (83%) than UL (59%). Route of administration was the most frequently observed OL category. The vast majority of the OL prescriptions were for ‘off‐patent’ products. One‐third of products prescribed were UL. CONCLUSIONS: The study confirms that medicines to children in hospital to a significant degree are being used outside or without authorisation, in spite of recent paediatric regulatory initiatives. More data are still needed on efficacy and safety of medicines used in children, data to be incorporated in the SmPC. In addition, suitable formulations are needed to ensure optimal dosing and adherence without risky manipulations.
format Online
Article
Text
id pubmed-5396330
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53963302017-04-25 Off‐label and unlicensed medicines to hospitalised children in Norway Teigen, Arna Wang, Siri Truong, Bich Thuy Bjerknes, Kathrin J Pharm Pharmacol Research Papers OBJECTIVES: The aim of this study was to investigate the use of off‐label (OL) and unlicensed (UL) medicines to hospitalised children in Norway, to add to the current knowledge on use of medicines in this vulnerable patient group. METHODS: The study was performed as a cross‐sectional prospective study. Medication was classified as on‐ or off‐label based on the comparison with the SmPC regarding age, indication, dosage, route of administration and handling of the product. UL products were classified as imported or pharmacy produced. KEY FINDINGS: More than 90% of children receiving medicines in our study were given OL or UL medicines. More patients received OL (83%) than UL (59%). Route of administration was the most frequently observed OL category. The vast majority of the OL prescriptions were for ‘off‐patent’ products. One‐third of products prescribed were UL. CONCLUSIONS: The study confirms that medicines to children in hospital to a significant degree are being used outside or without authorisation, in spite of recent paediatric regulatory initiatives. More data are still needed on efficacy and safety of medicines used in children, data to be incorporated in the SmPC. In addition, suitable formulations are needed to ensure optimal dosing and adherence without risky manipulations. John Wiley and Sons Inc. 2016-06-23 2017-04 /pmc/articles/PMC5396330/ /pubmed/27334565 http://dx.doi.org/10.1111/jphp.12581 Text en © 2016 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd on behalf of Royal Pharmaceutical Society This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Papers
Teigen, Arna
Wang, Siri
Truong, Bich Thuy
Bjerknes, Kathrin
Off‐label and unlicensed medicines to hospitalised children in Norway
title Off‐label and unlicensed medicines to hospitalised children in Norway
title_full Off‐label and unlicensed medicines to hospitalised children in Norway
title_fullStr Off‐label and unlicensed medicines to hospitalised children in Norway
title_full_unstemmed Off‐label and unlicensed medicines to hospitalised children in Norway
title_short Off‐label and unlicensed medicines to hospitalised children in Norway
title_sort off‐label and unlicensed medicines to hospitalised children in norway
topic Research Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396330/
https://www.ncbi.nlm.nih.gov/pubmed/27334565
http://dx.doi.org/10.1111/jphp.12581
work_keys_str_mv AT teigenarna offlabelandunlicensedmedicinestohospitalisedchildreninnorway
AT wangsiri offlabelandunlicensedmedicinestohospitalisedchildreninnorway
AT truongbichthuy offlabelandunlicensedmedicinestohospitalisedchildreninnorway
AT bjerkneskathrin offlabelandunlicensedmedicinestohospitalisedchildreninnorway